Alpha Tau to Participate in May Investor Conferences
Alpha Tau Medical (NASDAQ: DRTS), developer of the Alpha DaRT® cancer therapy, announced its CFO Raphi Levy's participation in two upcoming investor conferences in May 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alpha Tau Medical (NASDAQ: DRTS), developer of the Alpha DaRT® cancer therapy, announced its CFO Raphi Levy's participation in two upcoming investor conferences in May 2025. Levy will participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, from 3:30-4:00 PM ET in New York. Additionally, he will attend the Lytham Partners Spring 2025 Investor Conference virtually on May 29, 2025, for one-on-one meetings. Investors can schedule meetings with Mr. Levy at both conferences through their respective H.C. Wainwright and Lytham Partners representatives.
Details
News Market Reaction – DRTS
The recorded move for DRTS in the trading session of this news was -0.38%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
JERUSALEM, May 06, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will presentation in the following investor conferences in May 2025.
| Event: | H.C. Wainwright 3rd Annual BioConnect Investor Conference |
| Format: | Fireside Chat |
| Date: | May 20, 2025 |
| Time: | 3:30 – 4:00PM ET |
| Location: | New York, NY |
| Event: | Lytham Partners Spring 2025 Investor Conference |
| Format: | 1x1 Meetings |
| Date: | May 29, 2025 |
| Location: | Virtual |
Mr. Levy will be available for 1x1 investor meetings at both conferences. Please reach out to your H.C. Wainwright and Lytham Partners representatives to schedule.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT®
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Investor Relations Contact:
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.